Sentences with phrase «lymphoma survival»

Combining two different immunotherapy treatments could dramatically improve lymphoma survival.

A new precision medicine study aims to push leukemia and lymphoma survival rates ever higher while reducing side effects.

Specifically, the study ostensibly showed that HIV - negative people had an 80 percent Hodgkin lymphoma survival rate five years after diagnosis, but HIV - positive people survived at a rate of only 66 percent over the same timeframe.

Not exact matches

Survival times for non-Hodgkin's lymphoma, breast and colon cancers have improved dramatically over the past forty years, to the point where scientists are saying they are at «an amazing watershed» in understanding the disease.

«This is wonderfully serendipitous — our drug just happens to be able to overcome both of the biological mechanisms that are key to survival of aggressive lymphoma,» Dr. Melnick says, adding that the inhibitor completely eradicated DLBCL in mice in a short time, with no detectable side effects.

The researchers also affected mouse models with Mantle Cell Lymphoma, using the new platform to target cancer cells, induce cell death and dramatically improve overall survival.

Researchers found the strongest link between vitamin D levels and survival in breast cancer, lymphoma and colorectal cancer.

Dr Matt Kaiser, Head of Research at Leukemia & Lymphoma Research, said: «Unfortunately there have been no significant improvements in survival rates for acute myeloid leukemia in the last two decades.

Martensen initially thought it was lymphoma, cancer of the lymph glands, which has a higher survival rate than many other cancers.

«Five - year survival data: Brentuximab vedotin may be curative in some with Hodgkin lymphoma: Phase II trial suggests therapy should be standard of care for patients facing relapsed or treatment - resistant Hodgkin lymphoma.»

Exon - Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B - Cell / Follicular Grade 3 Lymphoma Patients Treated with Dose - Dense Chemoimmuno - therapy and CNS Prophylaxis.

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Use of exon - based transcriptome profiling to identify novel signaling pathways and survival - associated genes in diffuse large B - cell lymphoma.

Conditional survival and excess mortality after high - dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.

While clinical response did not correlate with either the Follicular Lymphoma International Prognostic Index 1 (FLIPI1) or FLIPI2, progression - free survival was significantly associated with both FLIPI1 and FLIPI2 (P =.0056 and P =.0344, respectively).

As a control, irradiation of wild - type mice resulted in 100 % mortality after a period of 9 months after irradiation, when the mice were 11 months old (Fig. 3 ⇓ shows the survival curve of the females alone for the purpose of simplifying the discussion below); and mortality was mainly attributable to the development of T - cell lymphomas (Table 3) ⇓.

Combined data from different types of lymphoma demonstrated 44 % of overall survival and 39 % of complete remission.

Given the very high survival rate for patients with Hodgkin lymphoma, many research studies now focus on learning how to eliminate potential late effects (e.g., secondary cancers) while maintaining excellent outcomes.

These findings suggest that activation of mTOR signaling contributes to tumor cell survival in ALK + ALCL, thus providing a potential therapeutic target in this lymphoma type.

Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase — Positive Anaplastic Large Cell Lymphoma

Both classical and nodular lymphocyte predominant Hodgkin lymphoma are highly curable, with survival rates between 90 and 95 percent.

Minimal Residual Disease (MRD) Status Following Induction Chemo - Immunotherapy Predicts Progression - Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance).

Progression - free survival and overall survival curves of patients with peripheral T - cell lymphoma not otherwise specified according to histone modifier gene mutations.

Long - term Tumor - free Survival With Untreated Primary Diffuse Large B - Cell Lymphoma of the Tonsil: A Report of 9 Cases.

High - Dose Chemotherapy Plus Transplant Not Recommended for DLBCL: The results of an Italian study report that treatment of high - risk diffuse large B - cell lymphoma (DLBCL) with abbreviated course of rituximab dose - dense chemotherapy plus high - dose cytarabine, mitoxantrone, and dexamethasone (R - MAD) plus carmustine, etoposide, cytarabine, and melphalan (BEAM) plus autologous stem cell transplantation compared with a full course of rituximab dose - dense chemotherapy did not improve overall survival.

Escalated BEACOPP Plus Rituximab in Advanced Hodgkin Lymphoma Fails to Improve Outcomes: The results of the phase III HD18 trial by the German Hodgkin Study Group determined that the addition of rituximab to an escalated regimen of BEACOPP did not improve progression - free survival (PFS) in patients with advanced - stage Hodgkin lLymphoma Fails to Improve Outcomes: The results of the phase III HD18 trial by the German Hodgkin Study Group determined that the addition of rituximab to an escalated regimen of BEACOPP did not improve progression - free survival (PFS) in patients with advanced - stage Hodgkin lymphomalymphoma.

Current practice is therefore based on findings from early - phase and retrospective primary CNS lymphoma studies, and extrapolations of survival data among patients with systemic B - cell lymphoma, Dr. Doorduijn said.

[3,4] Despite these advances, the late toxicities of chemotherapy and increased risk of secondary malignancies with RT have threatened the survival rates and quality of life of Hodgkin lymphoma patients.

Evidence demonstrates that local control, disease - free survival and overall survival are good with radiation treatment for MALT lymphomas.

Treatment for Hodgkin and non-Hodgkin lymphomas also differs, and survival rates do too.

Cats with lymphoma who are not treated with chemotherapy have an average survival time of 4 weeks once the diagnosis has been made.

With treatment, in dogs that feel well, about 80 % — 90 % of dogs with lymphoma attain a complete remission with an average survival of 12 - 14 months.

My Owen has «regular» lymphoma (median survival time 6 months) so he thinks it's great that he gets to eat whatever makes him happy.

Dogs showing clinical signs related to their lymphoma have a shorter survival than dogs who still are feeling well.

The most common form of lymphoma seen in dogs progresses rapidly and if untreated, the average survival time is about two months.

Abstract: Canine lymphoproliferative diseases include a very broad array of disorders ranging from clinically aggressive (acute leukemia) to indolent diseases with long survival times that may not require treatment (T zone lymphoma).

For most types of lymphoma, the median survival for patients receiving no treatment is 30 days.

For example, longer survival times and remission can occur in lymphoma, a common feline cancer.

Unfortunately, most dogs treated with chemotherapy for b - cell lymphoma see remission of only one year (median is 9 months), however, the two year survival rate is 20 %.

Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, et al. (2011) CD40 - Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma.

Mediastinal lymphoma in cats with feline leukemia carries a poor prognosis, with an average survival time of 3 months.

Numerous advances in veterinary oncology have been made over the last couple decades, improving survival times for canine lymphoma drastically.

Intestinal lymphoma tends to carry a worse prognosis and shorter survival times in most cases.

With standard of care treatment, B cell lymphomas with treatment may have an average survival of 9 - 12 months and those with T cell lymphomas may have an average survival of 6 - 9 months.

Rituximab Improves Overall Survival in Patients Treated with CODOX - M / IVAC for Burkitt Lymphoma (BL) and B - Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B - Cell Lymphoma and BL (BCL - U): A Single Center Experience and Review of the Literature